Novo Nordisk A/S (NVO) Receives Sell Rating from Zacks Investment Research

Novo Nordisk A/S (NVO) Receives Sell Rating from Zacks Investment Research


's stock had its "sell" rating reissued by Zacks Investment Research in a research report issued to clients and investors on Sunday, MarketBeat.Com reports. According to Zacks, "Novo Nordisk's third-quarter 2015 results were strong with revenues increased on the back of robust performance from Victoza and Levemir as well as significant contributions from Tresiba and Saxenda.



from Biotech News